Novel pharmaceutical cocrystal consisting of paracetamol and trimethylglycine, a new promising cocrystal former

Maeno, Yoshihiko; Fukami, Toshiro; Kawahata, Masatoshi; Yamaguchi, Kentaro; Tagami, Tatsuaki; Ozeki, Tetsuya; Suzuki, Toyofumi; Tomono, Kazuo

doi:10.1016/j.ijpharm.2014.07.008

Cited by 69 publications

(53 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chemicals that have been registered as generally recognized as safe (GRAS) by the FDA are also popular coformer choices because many of them have substantial amounts of available safety data. 48) Other coformers can be used for some specific purposes, such as visible clinical advantages, albeit with supporting evidence for their pharmaceutically acceptable safety and quality. Cocrystals containing multiple physiologically active substances, such as theophylline and caffeine, have been widely studied partly because of academic interests.…”

Section: Screening and Prediction Of Cocrystal Formationmentioning

confidence: 99%

Characterization and Quality Control of Pharmaceutical Cocrystals

Izutsu¹,

Koide²,

Takata

et al. 2016

Chem. Pharm. Bull.

Self Cite

View full text Add to dashboard Cite

Recent active research and new regulatory guidance on pharmaceutical cocrystals have increased the rate of their development as promising approaches to improve handling, storage stability, and bioavailability of poorly soluble active pharmaceutical ingredients (APIs). However, their complex structure and the limited amount of available information related to their performance may require development strategies that differ from those of single-component crystals to ensure their clinical safety and efficacy. This article highlights current methods of characterizing pharmaceutical cocrystals and approaches to controlling their quality. Different cocrystal regulatory approaches between regions are also discussed. The physical characterization of cocrystals should include elucidating the structure of their objective crystal form as well as their possible variations (e.g., polymorphs, hydrates). Some solids may also contain crystals of individual components. Multiple processes to prepare pharmaceutical cocrystals (e.g., crystallization from solutions, grinding) vary in their applicable ingredients, scalability, and characteristics of resulting solids. The choice of the manufacturing method affects the quality control of particular cocrystals and their formulations. In vitro evaluation of the properties that govern clinical performance is attracting increasing attention in the development of pharmaceutical cocrystals. Understanding and mitigating possible factors perturbing the dissolution and/ or dissolved states, including solution-mediated phase transformation (SMPT) and precipitation from supersaturated solutions, are important to ensure the bioavailability of orally administrated lower-solubility APIs. The effect of polymer excipients on the performance of APIs emphasizes the relevance of formulation design for appropriate use.

show abstract

Section: Screening and Prediction Of Cocrystal Formationmentioning

confidence: 99%

Characterization and Quality Control of Pharmaceutical Cocrystals

Izutsu¹,

Koide²,

Takata

et al. 2016

Chem. Pharm. Bull.

Self Cite

View full text Add to dashboard Cite

show abstract

“…Pharmaceutical co-crystal has gained more interest from pharmaceutical industries because they offer multiple opportunities for modification of the chemical and or physical properties of drug substances without making or breaking any covalent bonds. Indeed, many studies have reported the evident advantages of physicochemical properties of pharmaceutical co-crystal from pure drugs (Hiendrawan et al, 2016;Masuda et al, 2012;Maeno et al, 2014). Pharmaceutical co-crystal can be prepared by several methods.…”

Section: Introductionmentioning

confidence: 99%

Formation and Characterization of Sulfamethoxazole-Trimethoprim Cocrystal by Milling Process

2017

J App Pharm Sci

View full text Add to dashboard Cite

The purpose of this study was to describe and characterize co-crystal formation of sulfamethoxazole and trimethoprim. The co-crystal formation was carried out by solid state milling process. Co-crystal by solution cocrystallization and physical mixture were also prepared as a comparison. The potential co-crystalline phase was characterized by powder X-ray Diffraction (PXRD), thermal analysis differential scanning calorimetry (DSC), scanning electron microscope (SEM), and Fourier transform Infrared (FT-IR) spectroscopy. Effect of milling time on formation of co-crystal sulfamethoxazole and trimethoprim was investigated by DSC and PXRD analysis. The study showed that the milling process of sulfamethoxazole and trimethoprim in equimolar yielded the co-crystal. Intact co-crystal was obtained by solution co-crystallization with methanol. Prolongation of milling time accelerated the formation of co-crystal. Physical characterization showed that sulfamethoxazole and trimethoprim co-crystal demonstrated a unique powder X-ray diffraction, thermal and spectroscopic properties. The study concludes that the milling process induces equimolar co-crystal formation between sulfamethoxazole and trimethoprim. The transformation to co-crystalline phase is affected by milling time.

show abstract

“…. Compared with the identical peaks in co‐crystals prepared using the ground mixture process in recent reports , it can be found that all obtained particles are co‐crystals, i.e., PCA‐TMG co‐crystals were successfully prepared under the experimental conditions of the SAS process.…”

Section: Resultsmentioning

confidence: 99%

Co‐Crystal of Paracetamol and Trimethylglycine Prepared by a Supercritical CO₂ Anti‐Solvent Process

et al. 2018

View full text Add to dashboard Cite

Paracetamol (PCA) and trimethylglycine (TMG) were co‐crystallized and micronized by means of the supercritical anti‐solvent (SAS) process to improve the tabletability of PCA. The effects of operating conditions on particle properties were investigated in detail. Characterizations were performed to confirm the co‐crystal state of PCA‐TMG. The results indicated that the same crystal form with different crystal habits was prepared. The optimal PCA‐TMG co‐crystals presented a much larger tensile strength, higher drug content of PCA, and smaller particle size than those obtained using the ball milling (BM) process. The SAS‐processed PCA‐TMG co‐crystals showed an enhanced solubility, dissolution rate, and tableting performance compared to that of BM.

show abstract

Novel pharmaceutical cocrystal consisting of paracetamol and trimethylglycine, a new promising cocrystal former

Cited by 69 publications

References 27 publications

Characterization and Quality Control of Pharmaceutical Cocrystals

Characterization and Quality Control of Pharmaceutical Cocrystals

Formation and Characterization of Sulfamethoxazole-Trimethoprim Cocrystal by Milling Process

Co‐Crystal of Paracetamol and Trimethylglycine Prepared by a Supercritical CO₂ Anti‐Solvent Process

Contact Info

Product

Resources

About

Novel pharmaceutical cocrystal consisting of paracetamol and trimethylglycine, a new promising cocrystal former

Cited by 69 publications

References 27 publications

Characterization and Quality Control of Pharmaceutical Cocrystals

Characterization and Quality Control of Pharmaceutical Cocrystals

Formation and Characterization of Sulfamethoxazole-Trimethoprim Cocrystal by Milling Process

Co‐Crystal of Paracetamol and Trimethylglycine Prepared by a Supercritical CO2 Anti‐Solvent Process

Contact Info

Product

Resources

About

Co‐Crystal of Paracetamol and Trimethylglycine Prepared by a Supercritical CO₂ Anti‐Solvent Process